Biotech | February 27, 2022
HitGen completes research collaboration with MTPC
Collaboration with MTPC to discover novel hit compounds for multiple drug targets
Collaboration with MTPC to discover novel hit compounds for multiple drug targets
Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.
The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa
Tamper evident caps with incorporated RFID technology offer a significant reduction in RFID implementation costs
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
This new mandate builds upon and strengthens Azelis and Roquette’s global strategic partnership which spans multiple regions and industries.
Collaboration in the industry needs to be institutionalised to drive the growth.
Dr. Shah will lead strategic and operational clinical development of the company's diverse pipeline
Alchemee's flagship brand Proactiv@ is an iconic product synonymous with acne care
he financing was significantly oversubscribed with high demand from both existing and new investors.
Subscribe To Our Newsletter & Stay Updated
